153 related articles for article (PubMed ID: 15579048)
1. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists.
Alarcón de la Lastra C; Sánchez-Fidalgo S; Villegas I; Motilva V
Curr Pharm Des; 2004; 10(28):3505-24. PubMed ID: 15579048
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
Belvisi MG; Hele DJ; Birrell MA
Eur J Pharmacol; 2006 Mar; 533(1-3):101-9. PubMed ID: 16458290
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
4. PPAR-gamma in ulcerative colitis: a novel target for intervention.
Bertin B; Dubuquoy L; Colombel JF; Desreumaux P
Curr Drug Targets; 2013 Nov; 14(12):1501-7. PubMed ID: 23651165
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological activation of PPAR gamma ameliorates vascular endothelial insulin resistance via a non-canonical PPAR gamma-dependent nuclear factor-kappa B trans-repression pathway.
Zhang Y; Zhan RX; Chen JQ; Gao Y; Chen L; Kong Y; Zhong XJ; Liu MQ; Chu JJ; Yan GQ; Li T; He M; Huang QR
Eur J Pharmacol; 2015 May; 754():41-51. PubMed ID: 25687252
[TBL] [Abstract][Full Text] [Related]
6. 15-deoxy-Δ(12,14) -prostaglandin-J2 and ciglitazone inhibit TNF-α-induced matrix metalloproteinase 13 production via the antagonism of NF-κB activation in human synovial fibroblasts.
Lin TH; Tang CH; Wu K; Fong YC; Yang RS; Fu WM
J Cell Physiol; 2011 Dec; 226(12):3242-50. PubMed ID: 21344384
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock.
Abdelrahman M; Sivarajah A; Thiemermann C
Cardiovasc Res; 2005 Mar; 65(4):772-81. PubMed ID: 15721857
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer?
Luconi M; Cantini G; Serio M
Steroids; 2010; 75(8-9):585-94. PubMed ID: 19900469
[TBL] [Abstract][Full Text] [Related]
9. A step ahead of PPARγ full agonists to PPARγ partial agonists: therapeutic perspectives in the management of diabetic insulin resistance.
Chigurupati S; Dhanaraj SA; Balakumar P
Eur J Pharmacol; 2015 May; 755():50-7. PubMed ID: 25748601
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones and PPARγ agonists: time for a reassessment.
Cariou B; Charbonnel B; Staels B
Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
[TBL] [Abstract][Full Text] [Related]
11. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Wang M; Tafuri S
J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
[TBL] [Abstract][Full Text] [Related]
12. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
13. Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.
Ferrari SM; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Curr Med Chem; 2016; 23(7):636-49. PubMed ID: 26844838
[TBL] [Abstract][Full Text] [Related]
14. Anti-leukemic effects of PPARγ ligands.
Ryu S; Kim DS; Lee MW; Lee JW; Sung KW; Koo HH; Yoo KH
Cancer Lett; 2018 Apr; 418():10-19. PubMed ID: 29331412
[TBL] [Abstract][Full Text] [Related]
15. Targeting glioblastoma stem cells (GSCs) with peroxisome proliferator-activated receptor gamma (PPARγ) ligands.
Im CN
IUBMB Life; 2016 Mar; 68(3):173-7. PubMed ID: 26818439
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications.
Halabi CM; Sigmund CD
Am J Cardiovasc Drugs; 2005; 5(6):389-98. PubMed ID: 16259527
[TBL] [Abstract][Full Text] [Related]
17. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
18. The role of peroxisome proliferator-activated receptor-γ in breast cancer.
Kotta-Loizou I; Giaginis C; Theocharis S
Anticancer Agents Med Chem; 2012 Nov; 12(9):1025-44. PubMed ID: 22583414
[TBL] [Abstract][Full Text] [Related]
19. Evidence that peroxisome proliferator-activated receptor γ suppresses squamous carcinogenesis through anti-inflammatory signaling and regulation of the immune response.
Ren L; Konger RL
Mol Carcinog; 2019 Sep; 58(9):1589-1601. PubMed ID: 31111568
[TBL] [Abstract][Full Text] [Related]
20. Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-kappaB, heat shock factor 1, and Akt.
Zingarelli B; Hake PW; Mangeshkar P; O'Connor M; Burroughs TJ; Piraino G; Denenberg A; Wong HR
Shock; 2007 Nov; 28(5):554-63. PubMed ID: 17589386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
